Holly Prentice has over 20 years of experience developing cell lines, manufacturing processes and analytical methods for biologics. Her expertise also includes the identification and management of CMOs and CROs in these areas. Dr. Prentice has been involved in CMC development for a number of biotherapeutics and specializes in the selection and development of recombinant protein expression platforms and cell culture media. Before taking up consulting, she was Associate Director, Biologics Process Development at Momenta Pharmaceuticals where she oversaw the development of Biologics using proprietary technologies. Prior to this she held senior management positions at Millipore and helped develop a mammalian expression vector and cell line for biotherapeutic production. At Biogen Idec she led a team for the development of a commercial cell culture process as well as a Process development team for an early phase clinical candidate including the coordination of the CMC section of the IND filing.